An Assessment of Pyrexia, Patient Age and Weight; Pediatric Considerations

Area of Science:

• Pharmacology
• Toxicology
• Pediatrics

Background:

• Current endotoxin specifications for sterile drug products are based on adult data and a standard pyrogenic dose of 5 EU/kg for intravenous administration.
• Existing compendial methods consider patient body weight and administration route but may not account for differential responses in pediatric populations.

Purpose of the Study:

• To evaluate the implications of pediatric age and body weight on parenteral product endotoxin specifications.
• To assess if current endotoxin limits adequately protect children from pyrexia, considering potential age-related differences in endotoxin response.

Main Methods:

• Analysis of patient fever data from the FDA Adverse Events Reporting System (FAERS).
• Assessment of endotoxin response variability across different pediatric age groups (<1 to 18 years) and body weight ranges.
• Identification of age groups potentially more susceptible to endotoxin-induced pyrexia.

Main Results:

• Pediatric response to endotoxin is not uniform across body weight ranges within age groups.
• Children younger than 3-4 years appear to be more susceptible to endotoxin-induced pyrexia.
• Data suggest current specifications may not be optimal for all pediatric age groups.

Conclusions:

• The findings suggest a need to reconsider endotoxin specifications for pediatric patients, particularly for those under 3-4 years.
• Adoption of a worst-case scenario, such as the 5th percentile of population body masses, is recommended for children under 3-4 years to ensure adequate safety.
• Further research is warranted to refine endotoxin specifications for diverse pediatric populations.